Israel Institute for Biological Research will begin human clinical trials of its corona vaccine candidate Brilife from November 1 after receiving all compulsory approvals from the Ministry of Health and the Helsinki Committee, the Israeli Defence Ministry said.
The Helsinki Committee deals with research approval and human experiments. The Helsinki Committee is mandate to ascertain the well-being, and rights of trial volunteers and to secure that the experiment is conducted as per the approved medical guidelines and conduct, besides various domestic laws, rules, and regulations.
The guidelines are outlined in the Declaration of Helsinki and various episodic International Conventions.
The 3 stages of the Human Clinical Trial involving over 30,000 volunteers are likely to last till mid-2021 and if all goes well, the vaccine could be ready for mass use only after that.
This is a day of hope for the citizens of Israel, thanks to the IIBR researchers. Just 2 months before I received the first bottle of the vaccine. Today, we already have 25,000 vaccine doses and are starting the next phase of the test, said Benny Gantz.